Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Universal MRSA screening

This article was originally published in The Gray Sheet

Executive Summary

Evanston Northwestern Healthcare, a Chicago-area hospital system, decreased its methicillin-resistant Staphylococcus aureus infection rate by 69.6% (from 8.9 hospital-acquired infections per 10,000 patient-days to 3.9) in two years of implementing universal screening for MRSA in all hospital admissions, according to a recent study. Published March 18 in the Annals of Internal Medicine, the results compare favorably to a Swiss study that appeared in the Journal of the American Medical Association the previous week, showing no benefit from universal MRSA screening (1"The Gray Sheet" March 17, 2008, p. 13). Ebbing Lautenbach, University of Pennsylvania, notes in an accompanying AIM editorial that it is still premature for all hospitals to adopt universal screening, since the relative contribution of the test and concurrent interventions remains unclear. Evanston Northwestern uses BD's GeneOhm rapid molecular MRSA test

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts